Supplements That Help With Zepbound (Tirzepatide) Injection Site Reactions

What the Zepbound label reports

Zepbound is a once-weekly subcutaneous tirzepatide injection, a dual GIP and GLP-1 receptor agonist [1]. In the two pooled weight-management trials behind the label's adverse reaction table (958 on placebo, 630 on 5 mg, 948 on 10 mg, 941 on 15 mg, up to 72 weeks), injection site reactions were reported by 2% of placebo patients and by 6%, 8% and 8% of those on 5, 10 and 15 mg [1]. The label counts injection site bruising, erythema, pruritus, pain and rash under that heading and lists these reactions among those reported in at least 5% of treated patients [1]. Across seven phase 3 trials in 5,025 people with type 2 diabetes, treatment-emergent anti-drug antibodies developed in 51.1%, and more antibody-positive patients had hypersensitivity or injection site reactions, most nonserious and nonsevere [6].

What supplement research shows

The supplement studies available involve other skin conditions, surgical or injury-related inflammation, or laboratory cell work.

Bromelain has been reviewed for surgical trauma and other inflammatory conditions [2]. In cultured human mast cells, quercetin at 100 micromol/L inhibited histamine and prostaglandin D2 release and reduced IL-8, TNF and IL-6; two small open-label trials reported less contact dermatitis and photosensitivity [3]. In a double-blind trial, 79 nickel-allergic women took 5 g daily of an omega-3 lipid (70% EPA, 10% DHA) or control for three months; the difference in UV-induced suppression of nickel contact hypersensitivity was not statistically significant (mean difference 6.9%, 95% CI -2.1% to 15.9%) [4]. NHANES 2005-2006 data on 4,495 US adults found 41.6% with 25-hydroxyvitamin D at or below 20 ng/mL and an association between obesity and deficiency [5]. A 2016 review found Arnica montana more effective than placebo for post-traumatic and postoperative pain, edema and ecchymosis (bruising) in those settings [7].

What the label says to watch for

Zepbound is contraindicated in people with a known serious hypersensitivity to tirzepatide or its excipients, and anaphylaxis and angioedema have been reported after marketing [1]. In the pooled weight trials, 0.1% of treated patients had a severe hypersensitivity reaction versus none on placebo, and the label says to seek medical attention promptly and discontinue Zepbound if a hypersensitivity reaction is suspected [1]. The label directs injections into the abdomen, thigh or back of the upper arm, with the upper arm given by another person, and rotation of sites [1].